Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines

Mohammad N Uddin; Monzurul A Roni

doi:10.3390/vaccines9091033

Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines

Vaccines (Basel). 2021 Sep 17;9(9):1033. doi: 10.3390/vaccines9091033.

Authors

Mohammad N Uddin¹, Monzurul A Roni²

Affiliations

¹ College of Pharmacy, Mercer University, Atlanta, GA 30341, USA.
² College of Medicine, University of Illinois, Peoria, IL 61605, USA.

Abstract

In December 2019, a new and highly pathogenic coronavirus emerged-coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), quickly spread throughout the world. In response to this global pandemic, a few vaccines were allowed for emergency use, beginning in November 2020, of which the mRNA-based vaccines by Moderna (Moderna, Cambridge, MA, USA) and BioNTech (BioTech, Mainz, Germany)/Pfizer (Pfizer, New York, NY, USA) have been identified as the most effective ones. The mRNA platform allowed rapid development of vaccines, but their global use is limited by ultracold storage requirements. Most resource-poor countries do not have cold chain storage to execute mass vaccination. Therefore, determining strategies to increase stability of mRNA-based vaccines in relatively higher temperatures can be a game changer to address the current global pandemic and upcoming new waves. In this review, we summarized the current research strategies to enhance stability of the RNA vaccine delivery system.

Keywords: COVID-19; SARS-CoV-2; mRNA vaccine; stability; storage.

Publication types

Review